News & Events about Regenxbio Inc.
- Publication in Human Gene Therapy provides rationale for the use of microdystrophin expression levels as a surrogate endpoint reasonably likely to predict clinical benefit for AAV gene therapy intended for treatment of patients with Duchenne muscular dystrophy - - White paper submitted to the U.S...
REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients PR...
REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire ROCKVILLE, Md., Jan. 3, 2023 ROCKVILLE, Md., Jan. 3, 2023 /PRNewswire/ --REGENXBIO Inc. (Nasdaq: RGNX) today...
REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease PR Newswire ROCKVILLE, Md., Dec. 21, 2022 RGX-181 and RGX-381 are potential one-time AAV Therapeutics for the treatment of the CNS and ocular manifestations of...
REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I PR Newswire ROCKVILLE, Md., Dec. 8, 2022 RGX-111 is an investigational AAV...